Despite extensive regulatory engagement, many biotech companies face chemistry, manufacturing, and controls (CMC) and analytical deficiencies leading to complete response letters (CRLs) from the FDA. These setbacks highlight a crucial gap between sponsor expectations and evolving FDA standards, particularly in assay reproducibility, validation, and tech transfer readiness. Late-stage denials, such as Capricor Therapeutics’ recent experience with deramiocel, underscore the importance of addressing CMC and analytical issues early in the development process.
Industry experts suggest that in-house expertise and seamless collaboration with contract organizations are key to mitigating these challenges. Early-stage FDA feedback, while valuable, may not fully predict regulatory outcomes, emphasizing the need for thorough data integration and review. Discrepancies in analytical assay performance remain a common cause of CRLs, often stemming from inter-laboratory variability or inadequate method validation at commercial scale.
Bridging methods between development phases and manufacturing partners is essential to ensure assay comparability and method consistency. By proactively addressing these CMC and analytical challenges, biotech companies can enhance their regulatory readiness and position themselves for success in FDA reviews.
Read more on this topic here–> pharmtech.com
You might also like to read: Beyond Process Development: The Strategic CMC Challenges That Make or Break Biotech Startups